Skip to main content
      RT @RichardPAConway: Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish

      Richard Conway RichardPAConway

      3 years 10 months ago
      Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish study. But to greater extent in RA, narrowing mortality gap. @RheumNow #ACR22 Abstr#0711 https://t.co/JRh37u3uGm https://t.co/bA3Y5FLcRZ
      RT @uptoTate: Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular c

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular characterization of individual SLE pts and it's extraction of key molecular information to support more precise therapeutic decisions. #ACR22 @RheumNow https://t.co/FslQCVvptw https://t.co/NNlgZvllPC
      RT @DrTrishHarkins: 🔥ignite session🔥

      ❓Vessel wall MRI superior to TA-US in c-GCA❓

      🔥In c-GCA vessel wall M

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      🔥ignite session🔥 ❓Vessel wall MRI superior to TA-US in c-GCA❓ 🔥In c-GCA vessel wall MRI examines beyond the temporal arteries - ✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures Abst#0473 #ACR22 @RheumNow https://t.co/z8hYmqc95I
      RT @ericdeinmd: Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis
      KEEPsAKE 1&2 - RZB v PBO
      1407 pts -baseline 63%

      Eric Dein ericdeinmd

      3 years 10 months ago
      Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis KEEPsAKE 1&2 - RZB v PBO 1407 pts -baseline 63% enth, 28% dact, 20% both Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both Mean time to resolution decreased Results maintained through wk 52 @RheumNow https://t.co/RBubeuJoh8
      RT @RichardPAConway: Frey @CaoilfhionnMD @JuliePaikMD et al. Increasing duration of hold of MMF (esp >=10 days) incre

      Richard Conway RichardPAConway

      3 years 10 months ago
      Frey @CaoilfhionnMD @JuliePaikMD et al. Increasing duration of hold of MMF (esp >=10 days) increased response to SARS-CoV-2 vaccine. No difference in disease flare rates. @RheumNow #ACR22 Abstr#0797 https://t.co/5nxo2nLg80 https://t.co/sx1Roxngx9
      RT @RHEUMarampa: In this prospective cohort study by Dr Jacquez, there was a statistically significant inverse assoc bet

      sheila RHEUMarampa

      3 years 10 months ago
      In this prospective cohort study by Dr Jacquez, there was a statistically significant inverse assoc bet. average yearly HCQ dose and overall damage accrual 👇 Reassuring data. ☝️HCQ consistently proves to be a beneficial drug for #lupus #ACR22 @Rheumnow ABST#0982 @rheumarhyme https://t.co/nWHS9JtEsH
      RT @RichardPAConway: Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after comple

      Richard Conway RichardPAConway

      3 years 10 months ago
      Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after completion. Cited reasons: ongoing preparation/review of paper (50%), sponsor/funder problems (40%), unimportant/negative result (20%).@RheumNow #ACR22 Abstr#0827 https://t.co/V2a48iiAcn https://t.co/FLqQhjvlOx
      RT @Yuz6Yusof: #ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation Syndrome? A cohort study (N=43) reported MAS was mostly secondary to disease. 10/43 died. Super high Ferritin and raised Ferritin/CRP ratio were assoc with deaths @RheumNow https://t.co/JCH30pi4Vf
      The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
      Once in a while, I find an abstract at the ACR meeting that can potentially save lives and be implemented in practice now.   In Abstract #0939, Dr. J Patricia Dhar and colleagues shared data from a pilot study examining a new method to monitor cervical health in African American Women with Systemic Lupus Erythematosus (SLE) using a self-sampling brush to assess cervical cytology and human papilloma virus infection.
      RT @RichardPAConway: Boekel et al. Omicron variant assoc lower risk of severe COVID-19 in rheumatic disease than prior v

      Richard Conway RichardPAConway

      3 years 10 months ago
      Boekel et al. Omicron variant assoc lower risk of severe COVID-19 in rheumatic disease than prior variants EXCEPT rituximab treated patients. @RheumNow #ACR22 Abstr#0705 https://t.co/57Boj4SEt5 https://t.co/d2NoX83y5l
      RT @RichardPAConway: Mendel et al. Use of TMP-SMX prophylaxis in GPA from MarketScan and Medicaid. Used in <25% treat

      Richard Conway RichardPAConway

      3 years 10 months ago
      Mendel et al. Use of TMP-SMX prophylaxis in GPA from MarketScan and Medicaid. Used in <25% treated with RTX!? Female sex negatively assoc (OR 0.61)!? Steroid use in month prior associated (OR 4.31) @RheumNow #ACR22 Abstr#1071 https://t.co/56a0nHR8o4 https://t.co/5LygdFMrss
      RT @RichardPAConway: Kifayat et al. Response to Shingrix in rheumatic disease patients. 3/3 PsA, 5/6 SLE, 2/14 RA pts re

      Richard Conway RichardPAConway

      3 years 10 months ago
      Kifayat et al. Response to Shingrix in rheumatic disease patients. 3/3 PsA, 5/6 SLE, 2/14 RA pts reached protective level of 150U/ml. IgG titres and SI are 3x lower compared to non-rheumatic patients. @RheumNow #ACR22 Abstr#0800 https://t.co/Gm7ldxK5xd https://t.co/BlHuU2Jxk2
      ×